Wild-type IDH1/2, TERT promoter mutation, chromosome 7 gain, chromosome 10 loss, and epidermal growth factor receptor (EGFR) amplification are currently considered to be molecular hallmarks of glioblastoma, even despite the presence of histopathological features typically found in lower-grade diffuse gliomas [23]. This evidence concerns the gene IDH1 and glioblastoma.